Generalized pustular psoriasis (GPP) is a rare, chronic, and severe inflammatory skin
disorder characterized by sudden eruption of sterile pustules, often accompanied by …

Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence
ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with …

Introduction Generalized pustular psoriasis (GPP) is a rare form of psoriasis (less of 1% of
cases). Currently, GPP is recognized as a clinical entity, distinguished from plaque psoriasis …

Introduction Psoriasis is a chronic inflammatory skin disease often associated with several
comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes …

Guselkumab is a monoclonal antibody that selectively blocks the p19 subunit of interleukin
23 and has been approved for the treatment of moderate to severe psoriasis and active …

Background Molecularly targeted therapies, such as monoclonal antibodies (mAbs) and
Janus Kinase inhibitors (JAKis), have emerged as essential tools in the treatment of …

Introduction There is growing evidence that therapeutic drug monitoring of biologic therapy
is beneficial in psoriatic patients. With respect to ustekinumab, the available evidence has …

Background. Current psoriasis treatment goals emphasize achieving complete or near‐
complete skin clearance while preserving the quality of life, necessitating treatment …

Background Determining tumor necrosis factor-alpha inhibitors (anti-TNF-α) failure is still a
challenge in the management of moderate-to-severe psoriasis. Thus, our comprehensive …

Recent years have seen concerted efforts to understand the relation between psoriasis and
metabolic-associated fatty liver disease (MAFLD). Not only is MALFD diagnosed more often …